Explicit optimization of plan quality measures in intensity-modulated
  radiation therapy treatment planning by Engberg, Lovisa et al.
Explicit optimization of plan quality measures in
intensity-modulated radiation therapy treatment planning
Lovisa Engberg∗1,2, Kjell Eriksson2, Anders Forsgren1, and Bjo¨rn H˚ardemark2
1Optimization and Systems Theory, Department of Mathematics, KTH Royal
Institute of Technology, Stockholm SE-100 44, Sweden
2RaySearch Laboratories, Sveava¨gen 44, Stockholm SE-103 65, Sweden
Manuscript
January 24, 2017
Abstract
Conventional planning objectives in optimization of intensity-modulated ra-
diotherapy treatment (IMRT) plans are designed to minimize the violation of
dose-volume histogram (DVH) thresholds using penalty functions. Although
successful in guiding the DVH curve towards these thresholds, conventional
planning objectives offer limited control of the individual points on the DVH
curve (doses-at-volume) used to evaluate plan quality. In this study, we aban-
don the usual penalty-function framework and propose planning objectives that
more explicitly relate to DVH statistics. The proposed planning objectives are
based on mean-tail-dose, resulting in convex optimization. We also demonstrate
how to adapt a standard optimization method to the proposed formulation in
order to obtain a substantial reduction in computational cost.
We investigate the potential of the proposed planning objectives as tools for
optimizing DVH statistics through juxtaposition with the conventional plan-
ning objectives on two patient cases. Sets of treatment plans with differently
balanced planning objectives are generated using either the proposed or the
conventional approach. Dominance in the sense of better distributed doses-at-
volume is observed in plans optimized within the proposed framework, indicat-
ing that the DVH statistics are better optimized and more efficiently balanced
using the proposed planning objectives.
Keywords: Planning objectives, convex optimization, mean-tail-dose
1. Introduction
Conventional treatment planning in intensity-modulated radiation therapy (IMRT)
is often described as a time-consuming trial-and-error process, as it requires the
repeated solution of successively fine-tuned treatment plan optimization problems
before requirements on plan quality are met. The need for re-optimization partly
stems from a methodological difference between the mathematical planning objec-
tives and the clinical evaluation criteria. While conventional planning objectives
∗Corresponding author: loven140@kth.se
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2 Explicit IMRT treatment plan optimization
minimize the violation of dose statistics thresholds using (quadratic) penalty func-
tions, attention is rarely paid during plan quality assessment to the optimal level
of deviation. What rather influences plan quality is the actual dose statistics of the
dose distribution.
The vast amount of resources spent on treatment planning has motivated the de-
velopment of strategies for automated approaches that require limited user guidance.
A particular interest has recently grown in knowledge-based planning, where achiev-
able yet desirable dose statistics thresholds are predicted with machine-learning
techniques ahead of optimization. The expected outcome is a less need for fine-
tuning. Several methods have been proposed in this direction [2, 20, 21, 22, 25, 26]
and their success in producing high-quality treatment plans while reducing user
interaction has been investigated in subsequent evaluations [6, 9, 23]. Another sug-
gested approach is computerization of the typical trial-and-error scheme adopted by
treatment planners. While some of these methods are site-specific [28], others are
developed with the ambition to handle a large class of cases [13, 15, 27].
Still aiming for a less demanding planning process, we return to the underly-
ing inconsistency between mathematical planning objectives and clinical evaluation
criteria. We abandon the usual penalty-function framework and suggest planning
objectives that more explicitly relate to plan quality measures, in our case to dose-
volume histogram (DVH) statistics. The proposed planning objectives are based on
the wellknown concept of mean-tail-dose often referred to by the financial counter-
part conditional value-at-risk (CVaR). The use of CVaR-based objectives to obtain
qualified approximations of optimal value-at-risk (corresponding to DVH statistics)
is a frequent tool in finance [1, 18] since this leads to convex optimizaion. As for
treatment planning, mean-tail-doses were originally incorporated as constraints of
a penalty-function based formulation by Romeijn et al. [19]. The aim was to give a
tractable alternative to bounds on the mathematically intractable DVH statistics.
In following studies, mean-tail-doses have been used in, e.g., lexicographic optimiza-
tion of prostate plans [7] and as constraints in optimization of brachytherapy [16].
The present study investigates their merit as tools for optimizing the DVH statistics
to be assessed in the plan evaluation process.
Leaving the penalty-function framework has the attractive effect that dose statis-
tics thresholds are no longer required, neither is therefore the process of fine-tuning
them. Nevertheless, a need remains to find the objective weights that give the
desired tradeoff between conflicting evaluation criteria. Multicriteria optimization
(MCO) techniques, by which the procedure of balancing planning objectives can be
largely shortened, have been developed for the conventional case through rigorous
research (see, e.g., [3, 5, 8, 11] for recent advances). Although beyond the scope
of this study, we envisage that similar MCO techniques can be as advantageously
combined with the proposed planning objectives. The outcome would then be a
planning process that has little need for parameter tweaking.
The paper is organized as follows. In Section 2, the conventional and proposed
formulations of planning objectives are presented. Section 3 provides the set-up of
and results from a computational study where the two formulations are compared. In
Section 4, a method is described to handle the large-scale dimensions of the proposed
2. Formulation of planning objectives 3
optimization formulation. Existence of such a method is of utmost importance for
the clinical applicability of the proposed approach; however, this section can be
omitted by the reader who is only interested in the outcome of the method.
2. Formulation of planning objectives
Treatment plan MCO is generally formulated
minimize
x∈X
[
f1(x) · · · fK(x)
]T
,
where each of the K planning objectives f1, . . . , fK somehow relates to a plan eval-
uation criterion, and where X is the set of feasible treatment variables. We limit
this study to fluence map optimization (FMO), so that X equals the convex set
{x ∈ Rn : x ≥ 0} of physically realizable fluence maps of n beamlets. However,
the theory and methods applied permit the more general assumption that X be any
convex polytope of treatment variables that relate to voxel dose through a linear
mapping. In addition to FMO, that assumption is valid for, e.g., certain formulations
of sliding window optimization and spot weight optimization in proton therapy.
Treatment plan MCO formulations are usually solved under the notion of Pareto
optimality. A Pareto optimal plan is produced, among other techniques, by solving
a weighted-sum instance where the K planning objectives have been aggregated into
one using nonnegative objective weights. Each combination of weights results in a
different Pareto optimal plan, and all possible Pareto optimal plans form the Pareto
set. See [4] for a thorough introduction to MCO with focus on treatment planning.
This study concerns plan evaluation criteria relating to the cumulative dose-
volume histogram (DVH). As a function of the fluence map x, the DVH statistics
quantifies the least dose received by the hottest volume fraction vref of the region-
of-interest (ROI) r. A mathematical definition is
D(x; r, vref) = min{d ∈ R :
∑
j∈Vr:
pTj x≥d
∆rj ≤ vref},
where Vr collects the voxels of ROI r, ∆
r
j is the relative volume of r located in voxel
j, and pTj is the jth row of the dose deposition coefficient matrix so that p
T
j x is
the voxel dose received by voxel j. The compact notation D(x) is used throughout,
and D(x) is referred to as a dose-at-volume. A mathematical drawback of the
DVH statistics is its non-convexity and non-differentiability, making it intractable
for optimization purposes.
2.1. Conventional planning objectives
Conventional planning objectives are designed to push the DVH curve of a ROI
towards the point (dref, vref), with dref a DVH statistics threshold. Aiming to meet
maximum or minimum DVH criteria at volume fraction vref, they quadratically
penalize voxel overdose or underdose from dref while omitting the hottest vref or
coldest 1 − vref volume fraction. Thus, by construction, only the voxel doses that
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Figure 2.1: Voxel overdoses (top) and underdoses (bottom) (shaded) from the
threshold dref illustrated in the DVH graph. A conventional planning objective
q+(x) or q−(x) is the sum of the voxel overdoses or underdoses squared so that
when minimized, the DVH curve is pushed towards the point (dref, vref), aiming to
meet a maximum or a minimum DVH criterion at volume fraction vref.
fall between dref and the dose-at-volume D(x) are penalized, as seen in Figure 2.1.
The mathematical definitions are
q+(x; r, vref, dref) =
∑
j∈Vr:
dref≤pTj x≤D(x)
∆rj
(
pTj x− dref)2
for penalizing overdose, and
q−(x; r, vref, dref) =
∑
j∈Vr:
D(x)≤pTj x≤dref
∆rj
(
dref − pTj x
)2
for penalizing underdose. Compact notations q+(x) and q−(x) are used throughout.
A conventional planning objective is both non-convex and non-differentiable, yet
we want to draw the attention to another problematic aspect: its limited ability to
optimize or merely control the actual dose-at-volume D(x). For instance, large gaps
between dref and D(x) can be assigned relatively small penalties. The tool available
for the user to reach satisfactory plan quality is to iteratively modify the thresholds
and re-optimize the plan. This is a trial-and-error challenge, since the impact of dref
adjustments on the dose-at-volume is unclear. Another strategy, now formalized by
MCO techniques, is to choose a utopian dref (such as 0 Gy for healthy tissue) and
then fine-tune the objective weight to increase or decrease the impact of the penalty.
Nevertheless, the inconsistency remains between a conventional planning objective
and the pointwise dose-at-volume.
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Figure 2.2: Upper (top) and lower (bottom) mean-tail-doses in relation to dose-at-
volume D(x). The upper version d+(x) is the average of voxel doses greater than
D(x) and the lower version d−(x) is the average of voxel doses less than D(x).
When minimizing d+(x) or maximizing d−(x), D(x) is pushed to the left or right,
respectively.
2.2. Proposed planning objectives
To the extent that plan quality is assessed by dose-at-volume, an idealistic planning
objective is, naturally, equalling D(x) itself. Treatment plan MCO would then
amount to solving
minimize
x∈X
[
D1(x) · · ·Dk+(x)−Dk++1(x) · · · −DK(x)
]T
subject to Dk(x) ≤ uk, k = 1, . . . , k+,
Dk(x) ≥ lk, k = k+ + 1, . . . ,K,
(2.1)
where Dk(x) = D(x; rk, v
ref
k ), and where bounds lk and uk restrict Dk(x) to rele-
vant values. Here, the last K − k+ doses-at-volume are subjected to maximization
by minimizing the negatives. This idealized formulation is largely intractable: for
instance, the inherent non-convexity of D(x) renders (2.1) a non-convex problem
whose global minimum is difficult to find. It forms, however, the basis for the
proposed formulation, demonstrating how the usual penalty-function framework is
abandoned.
We arrive at the proposed formulation by using planning objectives that ap-
proximate dose-at-volume by upper or lower mean-tail-dose. The upper or lower
version respectively equals the average dose received by the hottest vref or coldest
1− vref volume fraction, i.e., the average of voxel doses greater or less than D(x) as
depicted in Figure 2.2. Their mathematical definitions can be established indepen-
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dently of D(x) (see Rockafellar and Uryasev [18] for the derivation for the financial
counterpart CVaR) as
d+(x; r, vref) =
min{α+ 1
vref
∑
j∈Vr
∆rj
(
pTj x− α
)
+
: α ∈ R}
for upper mean-tail-dose, and
d−(x; r, vref) =
max{α− 1
1− vref
∑
j∈Vr
∆rj
(
α− pTj x
)
+
: α ∈ R}
for lower mean-tail-dose, where ( · )+ denotes the positive part function max{ · , 0}.
Compact notations d+(x) and d−(x) are used throughout.
There are two favorable aspects of using mean-tail-doses as planning objectives:
the convexity of d+(x) and concavity of d−(x) (i.e., convexity of the negative of
d−(x)) making them suitable for optimization, and the relationship d−(x) ≤ D(x) ≤
d+(x) ensuring that the dose-at-volume is appropriately controlled. Treatment plan
MCO with proposed planning objectives becomes
minimize
x∈X
[
d+1 (x) · · · d+k+(x)−d−k++1(x) · · · −d−K(x)
]T
subject to d+k (x) ≤ uk, k = 1, . . . , k+,
d−k (x) ≥ lk, k = k+ + 1, . . . ,K,
a convex formulation whose Pareto optimal solutions provide pessimistic bounds on
the doses-at-volume of the optimized treatment plan. The formulation expands into
minimize
αk,dk∈R, x∈X
ηk∈Rmk
[
d1 · · · dk+ −dk++1 · · · −dK
]T
subject to αk +
1
vrefk
∑
j∈Vrk
∆rjη
k
j ≤ dk,
ηkj ≥ pTj x− αk, ηkj ≥ 0, j ∈ Vrk ,
k = 1, . . . , k+,
αk − 1
1− vrefk
∑
j∈Vrk
∆rjη
k
j ≥ dk,
ηkj ≥ αk − pTj x, ηkj ≥ 0, j ∈ Vrk ,
k = k+ + 1, . . . ,K,
dk ∈
[
lk, uk
]
, k = 1, . . . ,K,
(2.2)
with artificial mk-dimensional variables η
k introduced to linearly handle the positive
part function, denoting by mk the number of voxels in ROI rk; and with auxiliary
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variables dk introduced for clarity. It should be noted that we have slightly modified
the formulation by accepting both upper and lower bounds on dk. The desired (and
obtained) effect is removed incentive to minimize or maximize the kth mean-tail-
dose beyond these limits. In a Pareto optimal solution, dk takes the value of the
kth mean-tail-dose or, if any bound on dk is active, gives a pessimistic bound.
2.3. A note on planning constraints
Planning constraints impose bounds on doses-at-volume without providing incentive
to exceed the requirements. An upper bound is formulated by conventional means
as the constraint q+(x) ≤ 0, which corresponds to enforcing the DVH curve to reach
the point (dref, vref) where thus dref is the bound. Analogously, a lower bound is
imposed by q−(x) ≤ 0. In the proposed framework, upper and lower bounds on
doses-at-volume are formulated as upper or lower bounds on upper or lower mean-
tail-dose, respectively.
2.4. A note on maximum and minimum dose
Maximum or minimum doses are conventionally controlled by quadratically penal-
izing all voxel dose deviations from the threshold dref. The mathematical definitions
are
qmax(x; r, dref) =
∑
j∈Vr:
dref≤pTj x
∆rj
(
pTj x− dref
)2
for a maximum dose objective, and
qmin(x; r, dref) =
∑
j∈Vr:
pTj x≤dref
∆rj
(
dref − pTj x
)2
+
for a minimum dose objective, coinciding with q+(x) and q−(x) for vref = 0 and
vref = 1, respectively. The functions are convex and differentiable, but the previous
discussion regarding inconsistency with plan quality applies: the planning objectives
are successful in pushing the DVH curve towards dref, but have limited ability to
control the actual maximum or minimum dose.
The proposed framework allows direct optimization of the maximum and mini-
mum dose statistics. These are mathematically defined as
dmax(x; r) = min{d ∈ R : pTj x ≤ d,∀j ∈ Vr}
for maximum dose, and
dmin(x; r) = max{d ∈ R : pTj x ≥ d,∀j ∈ Vr}
for minimum dose. Convexity of dmax and concavity of dmin make them suitable for
minimization and maximization, respectively, and they can be integrated into (2.2)
without changing its characteristics.
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The construction of planning constraints for maximum and minimum dose is
analogous to the construction of dose-at-volume constraints. For instance, an upper
bound on maximum dose is given by qmax(x; r, dref) ≤ 0 or dmax(x; r) ≤ u. It should
be noted that these constraints are equivalent if dref = u.
3. Computational study
The proposed and conventional frameworks are juxtaposed in a preliminary com-
putational study comprising two patient cases. The aim is to get an indication of
the relative merit of the planning objectives as tools for optimizing DVH statis-
tics. To this end, we compare the distribution of doses-at-volume among treatment
plans generated in either the proposed or the conventional framework. Both patient
cases are limited to three planning objectives in order to allow comparison in three-
dimensional plots; however, planning constraints are added to increase complexity
and clinical relevance.
Weighted-sum instances of the proposed formulation in (2.2) are solved using a
MATLAB (MathWorks, Natick, Massachusetts) implementation of the method pre-
sented in Section 4. The conventional formulation is managed using the SQP solver
SNOPT [12] (Stanford Business Software, Stanford, California). Patient geometries
and other problem data, including dose deposition coefficient matrices, are exported
from RayStation (RaySearch Laboratories, Stockholm, Sweden).
3.1. Patient cases
The cases involve a prostate and a lung cancer patient. The patient geometries are
discretized into 74 877 and 106 465 voxels and the (five coplanar) beams into, in total,
1310 and 3923 beamlets, all using 5 mm resolution grids. Planning objectives are
chosen to minimize doses-at-volume to respectively the bladder, rectum and entire
healthy volume (referred to as the surrounding ROI), and the esophagus, lung and
surrounding ROI. The following requirements are added as planning constraints.
For the prostate case, a minimum dose of 68 Gy is required to the planning target
volume (PTV) and the maximum dose to the entire patient volume (external ROI)
must not exceed 72 Gy. For the lung case, a minimum of 66.5 Gy and a maximum
of 75 Gy are required to the PTV, and the maximum dose to the surrounding ROI
and spinal cord must not exceed 70 Gy and 50 Gy, respectively. All parameters are
listed in Table 3.1. It should be noted that, by restricting to planning constraints
for minimum and maximum dose, we ensure that the proposed and conventional
formulations define identical feasible regions.
3.2. DVH statistics of treatment plan cohorts
A cohort of differently balanced treatment plans was generated for both patient
cases and within both frameworks, resulting in four sets of plans; each treatment
plan is the result of a weighted-sum instance. The underlying four sets of objective
weight triplets (w1, w2, w3) all included the anchor (one wk equal to unity and others
to zero) and the balanced (all wk equal) triplets. The remaining combinations varied
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Table 3.1: Parameters for planning objectives (o) and constraints (c) used in the
prostate and lung case.
Prostate case
Proposed Conventional
ROI vrefk lk uk v
ref
k d
ref
k
o Surrounding d+ 5% 0 70 q+ 5% 0
o Bladder d+ 50% 0 70 q+ 50% 0
o Rectum d+ 20% 0 70 q+ 20% 0
c External dmax — — 72 qmax — 72
c PTV dmin — 68 — qmin — 68
Lung case
Proposed Conventional
ROI vrefk lk uk v
ref
k d
ref
k
o Surrounding d+ 5% 0 70 q+ 5% 0
o Lung d+ 25% 0 70 q+ 25% 0
o Esophagus d+ 20% 0 70 q+ 20% 0
c Surrounding dmax — — 70 qmax — 70
c PTV dmin — 66.5 — qmin — 66.5
c PTV dmax — — 75 qmax — 75
c Spinal cord dmax — — 50 qmax — 50
among the four sets and were sampled from successively refined symmetric grids to
have, as far as deemed possible, well-distributed plans. This strategy is primitive
in its nature and only convenient for two- or three-dimensional MCO; for higher
dimensions, it is recommended to apply techniques similar to those suggested in [4].
A total of respectively 55 and 159 plans were generated for the prostate case using
the proposed and conventional framework, and 34 and 130 for the lung case.
Each treatment plan was characterized by the three doses-at-volume intended
to be optimized. The distribution of such triplets in a three-dimensional coordinate
system is illustrated in Figures 3.1 and 3.2; the left, middle, and right subfigures
show different angles to enhance spatial perception and the corner of all-lowest value
within the axes limits has been marked with a circle. The figures give two indica-
tions of particular interest. First, the plans optimized using the proposed planning
objectives are superior to those generated within the conventional framework in the
sense that their convex hull is located closer to the all-lowest point. This dom-
inance is seen for both patient cases and suggests that the proposed framework,
despite its approximative nature, provided a more efficient tool for optimizing the
DVH statistics. Second, the proposed plans dominate each other to a remarkably
smaller extent than the conventional plans. For the lung case in particular, the
proposed plans span a wide region in the dose-at-volume domain, as opposed to the
conventional plans which give the impression of being randomly scattered.
A comment is needed regarding the accuracy in terms of fulfilment of planning
10 Explicit IMRT treatment plan optimization
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Figure 3.1: Dose-at-volume triplets [Gy] obtained in prostate plans generated using
the proposed (black dots) and conventional (red dots) planning objectives, and the
convex hull of the former. The left, middle, and right subfigures show different
angles of the plot. The doses-at-volume concern the surrounding ROI (S), bladder
(B), and rectum (R).
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Figure 3.2: Dose-at-volume triplets [Gy] obtained in lung plans generated using
the proposed (black dots) and conventional (red dots) planning objectives, and the
convex hull of the former. The left, middle, and right subfigures show different
angles of the plot. The doses-at-volume concern the esophagus (E), lung (L), and
surrounding ROI (S).
constraint. While each generated proposed plan strictly satisfied all requirements
on minimum and maximum dose, almost all conventional plans violated them. For
instance, the median minimum PTV dose of conventional plans admits an underdose
of 2.0 Gy in the prostate case and 3.6 Gy in the lung case. Violation within some
tolerance is standard; however, SNOPT had difficulties in satisfying the specified
tolerance in several tested instances. This property of conventional planning is
known, and is briefly discussed and explained in [10].
4. Numerical method
In this section, the issue of solving weighted-sum instances of (2.2) is discussed.
The instances belong to the class of linear programming (LP) problems for which
there exists several numerical optimization methods, some commercially available in
general-purpose implementations. However, the LP problems of this study require
more careful handling due to their size being proportional to the number of voxels.
With 5 mm resolution, the number of variables and constraints is easily brought to
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the order of 105. Below, we describe how the specific structure of (2.2) allows us to
eliminate number-of-voxels dependence in systems of linear equations of an interior-
point method. The reduced system is proportional to the number of beamlets which,
at least for fixed-gantry FMO, usually is orders of magnitude smaller than the
number of voxels.
In demonstrating how problem structure is accounted for, we give a brief de-
scription of a standard primal-dual interior-point method. The interested reader is
referred to, e.g., [24] for more thoroughgoing theory.
4.1. Interior-point method for specific structure
For convenience, we express a weighted-sum instance of (2.2) on the more compact
form
minimize
z,η
cTz z + c
T
η η
subject to Azzz +Azηη ≥ bz,
Aηzz + η ≥ bη,
z, η ≥ 0,
(4.1)
where η collects vectors ηk for all k and z collects the remaining variables. This
compact form preserves the key characteristic of (2.2): the identity coefficient matrix
of η in the second constraint stemming from constraints ηkj ≥ pTj x − αk and ηkj ≥
αk−pTj x. We should also note that the size of Azz is number-of-voxels independent,
and that Aηz is dense due to its rows containing p
T
j .
Associated with the (primal) optimization formulation (4.1) is its dual
maximize
yz ,yη
bTz yz + b
T
η yη
subject to ATzzyz +A
T
ηzyη ≤ cz,
ATzηyz + yη ≤ cη,
yz, yη ≥ 0.
An interior-point method applies Newton’s method to find a solution to the com-
plementary slackness conditions
yTz (Azzz +Azηη − bz) = 0, yTη (Aηzz + η − bη) = 0,
zT
(
cz −ATzzyz −ATηzyη
)
= 0, ηT
(
cη −ATzηyz − yη
)
= 0,
while ensuring strict primal and dual feasibility by appropriate step sizes; feasibility
and complementarity is necessary and sufficient for optimality. To this end, the
left-hand-sides of the conditions are perturbed by some µ > 0 that is successively
decreased as the method proceeds. Each iteration hence amounts to solving the
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system of linear equations
D1 −ZATzz 0 −ZATηz
YzAzz D2 YzAzη 0
0 −HATzη D3 −H
YηAηz 0 Yη D4


∆z
∆yz
∆η
∆yη
 =
−

ZD1e− µe
YzD2e− µe
HD3e− µe
YηD4e− µe

(4.2)
for some µ, where
Z = diag(z), D1 = diag
(
cz −ATzzyz −ATηzyη
)
,
Yz = diag(yz), D2 = diag (Azzz +Azηη − bz) ,
H = diag(η), D3 = diag
(
cη −ATzηyz − yη
)
,
Yη = diag(yη), D4 = diag (Aηzz + η − bη) .
The method converges to an optimal solution as the perturbation µ approaches zero.
Solving (4.2) is a computational challenge since the size of the bottom right
block is dependent on the number of voxels. However, accounting for the specific
structure of the bottom block permits to solve (4.2) in two relatively inexpensive
steps: by one solve with the substantially smaller Schur complement[
D1 −ZATzz
YzAzz D2
]
−
−
[
0 −ZATηz
YzAzη 0
] [
D3 −H
Yη D4
]−1 [
0 −HATzη
YηAηz 0
]
whose size is of the same order as the number of beamlets; and by one solve with the
bottom block. The computational gain comes from the fact that, as the composite
of four diagonal matrices,[
D3 −H
Yη D4
]−1
=
[
MD4 MH
−MYη MD3
]
with M = (D3D4 + YηH)
−1 diagonal, both the bottom block and its inverse merely
act as the inexpensive operation of scaling and adding two vectors. The result is a
dimensionality reduction of several orders of magnitude.
The main computational cost per iteration now lies in computing the dense
matrix product ATηzD3YηAηz appearing in the Schur complement. A technique is
suggested in [14] to accelerate convergence at the expense of multiple solves of (4.2)
with different right-hand-sides. Each additional solve is relatively inexpensive, since
it reuses the Schur complement (and its factorization) of the first solve. A decrease
in total computational cost is expected, since the accelerated convergence needs
fewer iterations to meet a certain accuracy.
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It should be mentioned that interior-point methods require starting points that
strictly fulfil inequality constraints. It is therefore convenient to introduce nonneg-
ative slack variables sz, sη, σz, and ση ≥ 0 in order to turn the non-trivial primal
and dual inequalities into equalities,
Azzz +Azηη − sz = bz, ATzzyz +ATηzyη + σz = cz,
Aηzz + η − sη = bη, ATzηyz + yη + ση = cη.
However, Newton’s method reduces to solving (4.2) with D1, D2, D3, and D4 in
the coefficient matrix respectively replaced by Σz = diag(σz), Sz = diag(sz), Ση =
diag(ση), and Sη = diag(sη). The computational effect on a single iteration is
therefore insignificant.
4.2. Performance of method implementation
We finalize this section by presenting the results of applying a MATLAB R2015a
implementation of the previously described interior-point method to the cases in-
troduced in Section 3. The progress of the method is shown in Table 4.1, with
the results of using the commercial software CPLEX 12 (IBM, Armonk, New York)
given as a reference. The total number of factorizations (one per iteration) and
solves (up to ten per iteration) is indicated in columns Nb fact and Nb solv. Dual
gap gives an upper bound on the gap between the current objective function value
(Obj val) and the optimum, and can be used as a stopping criterion. Residual is
the current primal and dual feasibility.
As seen in Table 4.1, the required number of iterations was 40 and 46 to meet
the accuracy criterion. On an Intel Core i7 2.80 GHz computer, computing and
factorizing the Schur complement took about 4.9 and 0.46 seconds for the prostate
case, resulting in a total running time of approximately 5 minutes. For the lung
case, 59.5 and 9.2 seconds translate into a running time of about 60 minutes. This
should be contrasted to the several hours required by CPLEX to solve each of the
cases, indicating the importance of accounting for problem structure when solving
(2.2).
5. Discussion
Treatment planning by conventional means is known to be a complex process in-
volving several re-optimizations with successively fine-adjusted parameters. In this
study, we have dealt with one possible cause: inconsistency between the criteria used
for optimizing and evaluating treatment plans. We propose planning objectives with
an explicit relationship to commonly used plan quality measures, in our case the
DVH statistics, and have thereby left the usual penalty-function framework used by
both the conventional and other suggested planning objectives [4, 17, 19].
In an initial computational study involving fluence map optimization of two
patient cases, we explored the potential of the proposed framework as a tool for
optimizing the DVH statistics. We hypothesized that the doses-at-volume (i.e., in-
dividual points on the DVH curve) of treatment plans optimized using the proposed
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Table 4.1: Iteration progress of the interior-point method (IP) described in Sec-
tion 4.1 applied to the prostate and lung cases. Dim is the size of the original
system of linear equations, whereas reduced dim and sparsity concern the Schur
complement.
Prostate case
Dim 459 638, reduced dim 3954, sparsity 11.16 %
Solver Dual gap Nb fact Nb solv Obj val Residual
IP 7.04e-01 29 107 57.684 1.13e-02
3.45e-02 33 127 57.433 8.89e-04
7.47e-03 35 133 57.424 2.28e-04
7.76e-04 37 142 57.421 3.56e-05
2.81e-06 39 156 57.421 1.27e-07
4.72e-08 40 159 57.421 2.22e-09
CPLEX 4.75e-05 26 — 57.421 3.77e-15
Lung case
Dim 746 649, reduced dim 11 799, sparsity 11.13 %
Solver Dual gap Nb fact Nb solv Obj val Residual
IP 7.10e-01 34 142 47.410 1.81e-02
7.36e-02 38 163 47.159 2.21e-03
9.50e-03 41 173 47.134 3.16e-04
1.36e-04 44 190 47.130 5.06e-06
1.94e-05 45 195 47.130 1.06e-06
3.29e-07 46 201 47.130 1.18e-08
CPLEX 1.10e-04 40 — 47.130 6.02e-06
planning objectives would be ranked as better than the doses-at-volume of plans
generated within the conventional framework. Dominance in this aspect was indeed
observed in cohorts of differently balanced plans, and in addition, a larger variety of
doses-at-volume was seen among plans optimized within the proposed framework.
The indication is that the DVH statistics are better optimized and more efficiently
balanced by the proposed planning objectives than by the conventional approach.
Despite its trial-and-error nature, it cannot be denied that the conventional plan-
ning process is able to produce treatment plans of high clinical relevance. Whether
the same is true for treatment plans optimized using the proposed framework was
beyond the scope of this preliminary study to explore. Examination of the clinical
acceptability of treatment plans is of high importance to draw further conclusions
regarding the proposed planning objectives and should be covered by future investi-
gation, for instance by looking more closely at dose distributions and DVH curves.
The analysis is even strengthened if deliverability constraints are added, which relate
to the physical limitations of treatment machines.
Clinical relevance also depends on the availability of fast optimization meth-
ods. The method described in Section 4 indicates that the proposed formulation
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is solvable if its structure is accounted for. The method is not as efficient as most
commercial treatment planning systems, and the computational cost is expected to
increase even more if deliverability constraints are added. However, given that the
conventional framework requires a considerable amount of manual overhead, longer
optimization running times could be acceptable if the planning process necessitates
less user guidance.
6. Conclusion
We have formulated planning objectives for treatment plan multicriteria optimiza-
tion with an explicit relationship to DVH statistics. This is in contrast to the
conventionally clinically used planning objectives by which the violation of DVH
statistics thresholds is minimized, offering limited control of individual points on
the DVH curve (doses-at-volume). The merit of the two planning approaches as
tools for DVH statistics optimization was investigated by exploring sets of differ-
ently balanced treatment plans generated using each approach. Dominance was
observed, in the sense of better doses-at-volume, among the sets of plans optimized
within the proposed framework. In addition, a larger variety of doses-at-volume was
seen in these sets of plans, indicating that the DVH statistics are better optimized
and more efficiently balanced using the proposed planning objectives.
Treatment planning with the proposed planning objectives amounts to solving
optimization problems whose dimensions are of the same order as the generally large
number of voxels. Availability of a numerical method that can handle these large
problems is of utmost importance for the validity of the proposed framework. We
have demonstrated how the problem structure can be used to adapt a standard
optimization method, and thereby obtain a reduction in computational cost by
several orders of magnitude.
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